Medical Research for Our Troops Act
Summary
HR3906 (Medical Research for Our Troops Act) would restore $1.181B in military medical research funding, but the bill has been stalled in the House Appropriations Committee since June 2025 with zero legislative movement. Real market data shows healthcare stocks declining 3-8% over 30 days due to broader sector headwinds, not this bill. No actionable trade signal exists.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR3906 is a stalled authorization bill with zero committee action since June 2025
- 2.The $1.181B funding restoration is not appropriated — it authorizes spending that requires separate appropriations bills
- 3.Healthcare stocks declining 3-8% over 30 days are driven by sector headwinds, not this dormant legislation
- 4.No actionable trade signal: the bill's passage probability is near zero in the current Congress
Market Implications
Zero market implications at current legislative stage. ($26.84), ($111.31), and ($316.60) are declining on unrelated healthcare sector pressure. Retail investors should ignore this bill as a trading catalyst. Any future movement would require the bill to advance out of committee and attract Republican support — track the House Appropriations Committee markup calendar, not stock prices.
Full Analysis
Rep. Carson (D-IN) introduced HR3906 on June 11, 2025, to restore $1.181B to the Defense Health Agency's research, development, test, and evaluation budget — specifically the Congressionally Directed Medical Research Programs (CDMRP). The bill targets a funding cut in the Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L. 119-4), reverting it to FY2024 levels. Since introduction, the bill has collected 48 cosponsors (all Democrats) and was referred to the House Committee on Appropriations — where it has remained for nearly 11 months without a hearing, markup, or vote.
The money trail is critical here: HR3906 is an authorization bill that would amend the existing appropriations act to restore spending levels. However, it does not directly appropriate new money — it authorizes the Secretary of Defense to obligate funds consistent with FY2024 levels. Actual disbursement requires the appropriations committee to include this language in a future spending bill. Given the bill's early-stage status and lack of committee action, there is effectively zero probability of near-term enactment.
Structural winners from this bill would be biopharma and medical device companies that participate in CDMRP's peer-reviewed grant programs — typically large pharma (, ), medical device manufacturers, and academic medical centers. However, no companies are named in the bill text, and CDMRP grants are competitive, not guaranteed. The defense healthcare sector (military treatment facilities, research labs) would be the direct beneficiary, but the stalled legislative path means ZERO current impact on revenue or earnings guidance.
Real market data confirms no bill-related impact: at $26.84 (-4.45% 30-day), at $111.31 (-7.47% 30-day), and at $316.60 (-3.65% 30-day) are all declining on broad healthcare sector weakness — likely tied to drug pricing policy uncertainty, patent cliff concerns, or macro rotation — not a stalled research funding bill no investor is watching.
Timeline: The bill requires (1) House Appropriations Committee markup and report, (2) House floor vote, (3) Senate companion bill and passage, (4) conference committee, and (5) presidential signature. Given zero actions in 11 months and a Democratic sponsor in a Republican-controlled House (119th Congress, Republican majority), the path to enactment is exceptionally narrow. No meaningful legislative catalysts expected before the 2028 elections.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND): $1.8B Department of State Federal Award
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Further Strengthening Actions Taken to Adjust Imports of Aluminum into the United States
This proclamation modifies the Section 232 tariff regime on aluminum imports by authorizing the Secretary of Commerce to establish a program that incentivizes new U.S. investment in primary aluminum production. Companies with approved onshoring plans can import primary aluminum at half the standard Section 232 duty rate, up to the anticipated annual output of their new or expanded facilities, with construction required to start by January 20, 2029. The action aims to boost domestic primary aluminum supply for national security and defense industrial base needs.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →